ArticleClinical rheumatology2026
Multidimensional immunoinflammatory profiles associated with rheumatoid arthritis-associated interstitial lung disease: a cross-sectional exploratory study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo investigate the associations of non-invasive peripheral blood inflammatory indices, cytokines, and lymphocyte subsets with the risk of rheumatoid arthritis (RA)-associated interstitial lung disease (RA-ILD), and to evaluate the auxiliary diagnostic discrimination of key biomarker panels.
methodsThis retrospective study enrolled 216 eligible patients (148 with RA alone, 68 with RA-ILD). After 1:1 propensity score matching (PSM), 114 patients were included. Variables were screened using the least absolute shrinkage and selection operator (LASSO) regression and multivariate logistic regression. A nomogram was developed and internally validated, with discriminative performance and calibration assessed by the area under the receiver operating characteristic curve (AUC), calibration curves, and bootstrap resampling. An exploratory ROC-derived cutoff of the model-predicted probability was further determined using the Youden index. An (extreme gradient boosting) XGBoost model was further constructed and combined with Shapley Additive exPlanations (SHAP) analysis for performance comparison and interpretability evaluation.
resultsIn multivariable analysis, CD4⁺ T cells, the systemic inflammation response index (SIRI), and the interleukin (IL)-2/IL-6 ratio were independently associated with RA-ILD. Restricted cubic spline (RCS) analyses confirmed that CD4⁺ T cells and the IL-2/IL-6 ratio exhibited non-linear correlations with RA-ILD risk, whereas SIRI showed an approximately linear positive trend. The nomogram achieved an AUC of 0.820, compared with 0.947 for the XGBoost model. A model-predicted probability cutoff of 0.494, corresponding to a nomogram score of 111.25 points, was associated with higher odds of RA-ILD (OR = 10.40, 95% CI: 4.51-25.59). SHAP analysis identified the IL-2/IL-6 ratio, SIRI, IFN-γ/IL-4 ratio, IL-17A, and CD4⁺ T cells as the leading contributors to model output.
conclusionPeripheral blood immune and inflammatory biomarkers are closely related to RA-ILD risk. The combination of peripheral blood immune and inflammatory biomarkers shows favorable discriminatory value and may provide a laboratory-based reference for auxiliary identification of RA-ILD. Key Points • This study explored RA-ILD from a multidimensional peripheral blood immune-inflammatory perspective. • CD4⁺ T cells, SIRI, and the IL-2/IL-6 ratio emerged as key variables in the multivariable analysis. • CD4⁺ T cells and the IL-2/IL-6 ratio showed non-linear associations with RA-ILD risk, whereas SIRI showed an approximately linear positive association. • The proposed models showed potential for RA-ILD risk assessment and warrant further validation.
Indexed as
Identifiers
42322541What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.